Personalis, Inc. ( PSNL ) stock is up in Tuesday’s premarket session after the company received Medicare coverage for its NeXT Personal molecular residual disease test for lung cancer surveillance. This positive development comes as the broader market rose, with the Nasdaq up 0.33% and the S&P 500 up 0.22% on the previous trading day.

The Catalyst

Personalis ( PSNL ) announced that its NeXT Personal test, which utilizes advanced genomic sequencing, will now be covered by Medicare for patients with Stage I to III non-small cell lung cancer. This coverage is expected to enhance patient access to the test, which tracks up to 1,800 mutations, providing a reliable tool for monitoring recurrence and residual disease.

The decision follows clinical validation from the TRACERx collaboration, which demonstrated the test’s high accuracy in identifying residual disease. CEO Chris Hall emphasized that this coverage not only broadens access for lung cancer patients but also serves as a catalyst for the company’s growth in the oncology market.

Technical Analysis

The stock is currently trading 16.6% below its 20-day simple moving average (SMA) and 13.7% below its 50-day SMA, indicating some short-term weakness. However, it is trading 4.3% above its 100-day SMA and 21.1% above its 200-day SMA, suggesting a stronger long-term trend. Over the past 12 months, shares have increased by 56.29% and are currently closer to their 52-week highs than their lows.

The RSI is at 39.64, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of a neutral RSI and a bearish MACD suggests mixed momentum, suggesting traders should watch for potential shifts.

Key Resistance: $10.00

Key Support: $7.50

The recent Medicare coverage for the NeXT Personal test is a significant milestone for Personalis ( PSNL ), enhancing its market position and providing a pathway for increased adoption of its advanced genomic solutions. This move is crucial as lung cancer remains a leading cause of cancer death in the U.S., with a substantial number of new cases diagnosed annually.

Earnings & Analyst Outlook

Investors are looking ahead to the next earnings report on February 26, 2026.

EPS Estimate: Loss of 29 cents (Down from Loss of 23 cents YoY)

Revenue Estimate: $17.55 million (Up from $16.80 million YoY)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $11.78. Recent analyst moves include:

Guggenheim: Buy (Raises Target to $13.00) (Jan. 26)

BTIG: Buy (Maintains Target to $12.00) (Jan. 9)

Morgan Stanley: Equal-Weight (Raises Target to $11.00) (Dec. 2, 2025)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Personalis ( PSNL ), highlighting its strengths and weaknesses compared to the broader market:

Momentum: Bullish (Score: 92.11) — Stock is outperforming the broader market.

The Verdict: Personalis’s Benzinga Edge signal reveals a strong momentum score, indicating that the stock is performing well relative to the market. This positive momentum, coupled with the recent Medicare coverage news, positions the company favorably for future growth.

Top ETF Exposure

ARK Genomic Revolution ETF ( ARKG ) : 6.35% Weight

Significance: Because PSNL carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

PSNL Price Action: Personalis ( PSNL ) shares were up 14.90% at $8.99 during premarket trading on Tuesday, according to Benzinga Pro data.

Image via Shutterstock